China’s Qiming Venture Partners Leads $37M In AI-Enabled Drug Discovery Start-Up

Insilico Medicine, a Hong Kong-based start-up specialized in next-generation artificial intelligence (AI) technology for drug discovery, has raised US$37 million in a series B round of financing led by Chinese venture capital firm Qiming Venture Partners, according to a statement released on Tuesday.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Register Now

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in

China Expert network